Pharma
Cambridge AI Club - October Theme - Commercialisation of AI
The AI Club brings together the Biomedical AI and Machine Learning community in Cambridge to discuss common themes and explore different topics and methodologies. ...
From farms to factories: patient journey to Pulmonary Fibrosis
Rosemary’s health journey has been anything but straightforward. After enduring three years of painful breathing tests with countless visits to her GP and specialist consultants, she was finally given a diagnosis 12 months later—a name that escaped her when her granddaughter asked. Havi...
Dr Xand takes a visit to the BioResource laboratory
D-CYPHR ambassador checked out the exciting new technology used to decode the DNA provided by our volunteers. ...
Nxera Pharma to receive US$35 Million from Neurocrine Biosciences upon positive phase 2 data for partnered Schizophrenia candidate NBI-1117568
Tokyo, Japan and Cambridge, UK - Nxera Pharma Co., Ltd. - formerly known as Sosei Group or Sosei Heptares – announces it will receive a US$35 million payment from Neurocrine Biosciences, triggered by the successful completion of the Phase 2 trial with NBI-1117568 (NBI-‘568) in adults wi...
Milner Therapeutics Institute 2024 symposium visual branding
I've been visual branding for the Milner Therapeutics Institute symposium since 2016 and designed the Milner Therapeutics Institute logo and built the original website (now in the hands of Nikki). I've been lucky to work each year with the team to develop their event branding. ...
Transforming Healthcare: Navigating medical device regulations for startup success
In this episode we dive into medical device regulations with Sam Shelley, Quality Manager Consultant. Sam sheds light on the the hurdles startups encounter when implementing Quality Management Systems (QMS) and ensuring their regulatory processes align with product development. ...
Nxera Pharma notes positive topline results from its Phase 2 clinical study in adults with schizophrenia
Tokyo, Japan and Cambridge, UK - Nxera Pharma Co., Ltd. – formerly known as Sosei Group or Sosei Heptares – notes the announcement by its partner Neurocrine Biosciences Inc., that NBI-1117568 (NBI-‘568) has delivered positive topline results from its Phase 2 clinical study in adults wit...
Antibody-drug conjugates: where are we now, where is it heading, and how can you get ahead of the opportunities and challenges with key stakeholders?
Antibody-drug conjugates (ADCs) hold great promise for the targeted treatment of cancer, and the market is expected to grow significantly in the upcoming years driven by the continued breakthroughs in ADC technologies. ...
Introduction to Managing Life Science Projects
Audience People newly appointed as Project Managers, Service Organisation Account Managers, or science/technical staff who need to add the management of a project to their current role. Also, it will help people who contribute to projects to understand what is invol...
Biological Safety: Management and Practice (IOSH Approved) 2 day course
Audience The course is predominantly aimed at those fairly new to the role and mostly focuses on work at ACDP containment levels 1 and 2 and work with GMOs. However, experienced BSO will also benefit from the course. Duration A two day course. ...